ADR volume etc, page-5

It starts. Good write up mentioning BP report.


2208 GMT - By securing fast-track approval in the US for its VivaGel treatment for
bacterial vaginosis, Starpharma (SPL.AU) is in a stronger position to find a partner,
says Bell Potter. VivaGel's Qualified Infectious Disease Product and Fast Track
designation means it's eligible for an additional five years of market exclusivity over
the standard period and priority review, which would shorten the FDA review time to six
months versus the standard 10 months, Bell Potter says. "We intend to re-instate the US
opportunity of VivaGel as an acute treatment of bacterial vaginosis in our model, which
represents an upside to our current valuation of A$1.05/share for StarPharma," the
brokerage says. Its buy call is unchanged. SPL last traded at A$0.765.
([email protected]; @dwinningWSJ)

(END) Dow Jones Newswires